Lenalidomide Faran

Lenalidomide, the active ingredient in Lenalidomide Faran, is a immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q) and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Faran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cell or lymphoid proliferation.

- Multiple myeloma: improves progression‑free survival and overall response rates in eligible patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle cell lymphoma: enhances response when combined with rituximab in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Thromboembolic events: blood clots such as deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary malignancies: emergence of new cancers, including acute myeloid leukemia.

Before initiating therapy, clinicians should consider several safety measures.

- Pregnancy contraindication: drug is classified Category X; avoid use in pregnancy. - Teratogenic risk: ensure effective contraception for both male and female patients of reproductive potential. - Blood count monitoring: perform regular CBC to detect neutropenia or anemia. - Thromboembolism prophylaxis: assess risk and consider anticoagulation in high‑risk patients. - Renal impairment adjustment: evaluate kidney function and modify dosing as needed. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lenalidomide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lenalidomide exposure. - P‑glycoprotein inhibitors (e.g., verapamil): can raise plasma concentrations. - Anticoagulants (e.g., warfarin) when combined with high thrombotic risk: may exacerbate clotting.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Other myelosuppressive agents (e.g., chemotherapy): increase risk of cytopenias. - Live vaccines: reduced efficacy and potential infection risk.